Evidence mapPaperPMID 23250357Full record

Trial reportDiabetes2013

The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes.

Galina Smushkin, Matheni Sathananthan, Francesca Piccinini, Chiara Dalla Man, Jennie H Law, Claudio Cobelli, Alan R Zinsmeister, Robert A Rizza, Adrian Vella

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00951899. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00951899 phase4completed

The Effect of Colesevelam Hydrochloride on Disposition Index and Incretin Concentrations in Subjects With Type 2 Diabetes Using a Double-blind, Placebo-controlled, Parallel-group Study Design

Ran2009Enrolled38Registered outcomes9Posted comparisons2ConditionsType 2 DiabetesArmsColesevelam, diet, Metformin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 84 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Bile acids and microbes in metabolic disease.World journal of gastroenterology · 2022
    Review
  11. Article
  12. Article
  13. Insulin Pulse Characteristics and Insulin Action in Non-diabetic Humans.The Journal of clinical endocrinology and metabolism · 2021
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Galina SmushkinDivision of Endocrinology, Diabetes and Metabolism, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Matheni Sathananthan
Francesca Piccinini
Chiara Dalla Man
Jennie H Law
Claudio Cobelli
Alan R Zinsmeister
Robert A Rizza
Adrian Vella
Mayo Clinic · USUniversity of Padua · IT

Funding

The regulation of fasting glucose metabolism in people with and without prediabetesR01DK078646 · MAYO CLINIC ROCHESTER · 2025 to 2025
$667k
NIDDK NIH HHS DK-78646NIDDK NIH HHS DK-82396NIDDK NIH HHS R01 DK078646NIDDK NIH HHS R01 DK082396
6 · The paper itself

Abstract

We designed an experiment to examine the effect of bile acid sequestration with Colesevelam on fasting and postprandial glucose metabolism in type 2 diabetes. To do so, we tested the hypothesis that Colesevelam increases the disposition index (DI), and this increase is associated with increased glucagon-like peptide-1 (GLP-1) concentrations. Thirty-eight subjects on metformin monotherapy were studied using a double-blind, placebo-controlled, parallel-group design. Subjects were studied before and after 12 weeks of Colesevelam or placebo using a labeled triple-tracer mixed meal to measure the rate of meal appearance (Meal Ra), endogenous glucose production (EGP), and glucose disappearance (Rd). Insulin sensitivity and β-cell responsivity indices were estimated using the oral minimal model and then used to calculate DI. Therapy with Colesevelam was associated with a decrease in fasting (7.0 ± 0.2 vs. 6.6 ± 0.2 mmol/L; P = 0.004) and postprandial glucose concentrations (3,145 ± 138 vs. 2,896 ± 127 mmol/6 h; P = 0.01) in the absence of a change in insulin concentrations. Minimal model-derived indices of insulin secretion and action were unchanged. Postprandial GLP-1 concentrations were not altered by Colesevelam. Although EGP and Rd were unchanged, integrated Meal Ra was decreased by Colesevelam (5,191 ± 204 vs. 5,817 ± 204 μmol/kg/6 h; P = 0.04), suggesting increased splanchnic sequestration of meal-derived glucose.

Indexed as

AllylamineAnticholesteremic AgentsBlood GlucoseColesevelam HydrochlorideC-PeptideDiabetes Mellitus, Type 2Double-Blind MethodFastingFemaleGlucagonGlucagon-Like Peptide 1GlucoseHumansInsulinInsulin ResistanceMaleAllylamineAnticholesteremic AgentsBlood GlucoseColesevelam HydrochlorideC-PeptideGlucagonGlucagon-Like Peptide 1GlucoseInsulin

Identifiers

PMID23250357
PMCPMC3609563
OpenAlexW2141548864

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.